Pat Brady is Genome BC’s Executive Director, Industry Programs, focused on advancing genomic and other life science tools and technologies from the research stage through to commercialization.

For more than 30 years, Pat has been involved with growing innovative companies, in particular, life science firms. His experience as a venture capitalist and in operations provides hands‐on practice evaluating IP, product development and the market potential of life science technologies.

Pat spent six years in financial and operating roles with Inex Pharmaceuticals (now Arbutus BioPharma) and a clean tech company, DynaMotive Technologies. As a venture capitalist with Growthworks for 18 years, Pat served as a Board Director or Observer for over 13 life science firms. He has accumulated broad insight for many successful management practices and strategic issues encountered along the commercialization pathway.

Pat brings with him a deep life science and investor network across Canada and internationally. He was the co‐founder of the BIOTECanada Investor Summit (Whistler, BC) and has gained valuable exposure to the innovator community as an EIR with VentureLabs. He’s also served as an expert panel participant for many “pitch” events including the CECR program.

Chang Han is a consultant to Genome BC’s I² Fund. He is also the Lead Entrepreneur in Residence (EiR) at entrepreneurship@UBC (e@UBC), the startup venture building accelerator at the University of British Columbia (UBC).  Chang is an EIR for Accelerate IP, the IP grant program administered by New Ventures BC for B.C., Yukon, Northwest and Nunavut Territories. Chang is also a part-time faculty member at the British Columbia Institute of Technology (BCIT). Additionally, Chang is an active entrepreneur and angel investor with projects in stealth mode, and was previously a litigation attorney before going in-house to manage the intellectual property portfolio of an international bank.  He loves startups and scaleups and makes a difference in the world by helping to solve the hard problems.